Summer Training 2018

Are you biotechnology student looking for summer training in industry? We in collaboration with industry are organizing Summer Training in Biotechnology in various domains. Summer Training will commence from June 2018 and are available till September 2018. Summer Projects will be live and will be conducted in association with top companies.

You can choose any one of the following projects. You will be working with team of analysts who will be helping you conduct patent research and develop detail reports on chosen projects.

List of Available Projects

  1. Rice Genomics
  2. Human Typoid Conjugate Vaccine
  3. Agrobacterium-mediated transformation
  4. Human Pneumococcal Conjugate Vaccines
  5. Ritonavir: Treating HIV/AIDS
  6. Influenza Genome
  7. Atazanavir: Treating HIV/AIDS

Duration and Fees

One Month : Fees – 8000 INR

Two Months : Fees- 15000 INR

Three Months : Fees – 18000 INR

Location : Delhi

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com

Summer Training for Biotech : Recombinant DNA Technology  : Rice Genomics

Rice is a hugely important food crop for the world’s population.  It’s importance goes beyond food security; rice plays a large economic and cultural role as well in many countries.

A program (MEGABLAST) was used to identify nucleotide sequences that are highly similar to sequences in the rice genome. To qualify as a “hit”, the sequence had to be at least 150 nucleotides in length and have a a probability value of 1e-200 or less. Matches with such values are highly statistically significant.  Major findings include:

  • 182 granted patents recite rice sequences; of these, 151 (83%) have claims that explicitly claim rice sequences or sequences highly similar to rice.
  • Yet, only 0.26% of the rice genome and less than 1.0% of coding sequence is claimed in these U.S. patents.
  • While there are somewhat more patent applications – 313 U.S. applications – that recited rice sequences in claims, the sequences encompass about 74% of the rice genome. The high degree of genome coverage is largely due to “bulk sequence applications” that are published with claims to large numbers of sequences.

Projects Highlights

  • Analyse Patenting by top companies : Monsanto, Syngenta, Dupont, BASF and Bayer
  • Understand Patenting on Rice Genomics
  • Learn new tools and technology to analyse gene sequences

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com

Summer Training for Biotech :Human Typoid Conjugate Vaccine

The scope of this report is to detect patterns of patenting activity and innovation in the area of vaccine research and manufacturing.

Typhoid fever is a systemic infection caused by the bacterium Salmonella enterica, serovar typhi (S. typhi). This worldwide illness is transmitted by the ingestion of food or water contaminated by excreta from infected person or chronic carriers.  Enteric fevers also include paratyphoid fever caused by strains of three species of Salmonellae that are Salmonella paratyphi A, S. paratyphi B (or S. schottmuelleri) and S. paratyphi C (S. hirschfeldii). The paratyphoid bears similarities with typhoid fever, but its course is more benign.

Apart from the heat‐killed injectable whole‐cell S. typhi vaccine used as far back as 1896 and still licensed today in several countries in spite of its high reactogenicity, two recent vaccines are currently recommended by the WHO for the prevention of typhoid. The injectable Vi polysaccharide vaccine (US5204098) was developed at the NIH in the 80’s and licensed to Sanofi‐Pasteur (Typhim TM, Sanofi‐Pasteur; Typherix TM, GlaxoSmithKline; TypbarTM, Bharat Biotech). The oral live attenuated Ty21a vaccine (US4632830) was developed at the “Swiss Serum and Vaccine Institute Berne” in the 80’s and licensed to Berna Biotech now acquired by Dutch company Crucell (Vivotif TM, Crucell).

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com

Summer Training for Biotech :Agrobacterium-mediated transformation

Many methods and techniques can be used to transfer genes into cells. In agricultural plant biotechnology, the most widely utilized technique is Agrobacterium-mediated transfer, which is heavily patented.  Use of patented technologies can restrict the deliverability of products.

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com

Summer Training for Biotech : Pneumococcal Conjugate Vaccines

Pneumococcal conjugate vaccines (PCV) are used to protect infants and young children. There are currently three PCV vaccines available on the global market: Prevnar (called Prevenar in some countries), Synflorix and Prevnar 13.

 

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com

Summer Training for Biotech : Influenza Genome

The possibility of pandemic influenza arising from the avian influenza virus, H5N1, is of critical importance for global public health.

  • One-half of the patents are directed to equine influenza virus (assignee = Heska Corp.);
  • None appear to claim the H5 subtype of segment 4, which encodes hemagglutinin (HA) or the N1 subtype of segment 6, which encodes neuraminidase (NA);
  • Of the two patents that claim HA sequences, one claims sequence encoding the signal peptide region from HA1 and HA3 (US 6245532), and the other claims an antigenic fragment of HA2 and HA3;

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com

Summer Training for Biotech : Ritonavir: Treating HIV/AIDS

Ritonavir is an is an antiretroviral drug mainly used as a protease inhibitor in combination therapies treating HIV/AIDS.  A major goal of the project is to highlight the technology timeline for Ritonavir from the first filing of this compound to the present filings. Ritonavir is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.  Ritonavir is included in the WHO Model List of Essential Medicines (EML).

The originator company is Abbott Laboratories, which markets Ritonavir under the brand name Norvir, or in combination with the protease inhibitor Lopinavir, as Kaletra or Aluvia.  The U.S. Food and Drug Administration (FDA) approved the drug in March 1996 for oral solution and in June 1999 for capsules.  Abbot later received FDA and European Medicines Agency (EMEA) approval in 2010 for a heat‐stable formulation of a 100mg Ritonavir tablet.  This has particular importance for developing countries with elevated ambient temperatures.

Projects Highlights

  • Analyse Patenting by Abbot Laboratories
  • Learn new tools and technology to analyse narrower technologies related to the synthesis, characterization, and dosage forms.

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com

Summer Training for Biotech : Atazanavir

Atazanavir is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. Atazanavir is included in the WHO Model List of Essential Medicines (EML).

A major objective of this project is to examine the evolution of the patent environment protecting Atazanavir from the first filing of this compound in July 1995 by Novartis (then CIBA-GEIGY) (US5753652A) to the present filings in which additional patent families attempt to protect subsequent innovations to the compound, variants and derivatives, combinations with other chemicals, methods of production, further therapeutic indications, etc.

The project goes on to cover various analytic approaches to probe the collection for nuggets of intelligence. It separates the activity of the developer of Atazanavir (Novartis and its licensee Bristol-Myers Squibb) from activity of other entities, and compares the two across a timeline. It identifies the inventions that reference standard phases of drug development including: composition discovery, establishing biological targets (pathway modulation effects), developing synthetic methods, formulating for treatment, describing best disease indications, investigating combinations, improving synthesis, and broadening uses.

Contact Person :

Miss Divya Marwah

Summer Training Cordinator

Phone Number : 8860513985

Email : divya@iipta.com